Aggressive Natalizumab Treatment For Jc Virus-Negative Relapsing-Remitting Multiple Sclerosis? Cost-Effectiveness Of First-Line Versus Second-Line Natalizumab Treatment
Abstract
Authors
R.B. McQueen K.V. Nair T.L. Vollmer J.D. Campbell